Zenapax (Daclizumab) - Summary

ZENAPAX SUMMARY

ZENAPAX^® (Daclizumab) is an immunosuppressive, humanized IgG1 monoclonal antibody produced by recombinant DNA technology that binds specifically to the alpha subunit (p55 alpha, CD25, or Tac subunit) of the human high-affinity interleukin-2 (IL-2) receptor that is expressed on the surface of activated lymphocytes.

ZENAPAX is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants. It is used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.

The efficacy of ZENAPAX for the prophylaxis of acute rejection in recipients of other solid organ allografts has not been demonstrated.

ZENAPAX NEWS HIGHLIGHTS

Media Articles Related to Zenapax (Daclizumab)

EHealth Global Shows Dramatic Growth Of EHealthConnect™ Services For Solid Organ Transplant Departments
Source: Transplants / Organ Donations News From Medical News Today [2008.10.01]

CMV Disease In Solid Organ Transplant Recipients: A Proactive Approach To Prevention
Source: Transplants / Organ Donations News From Medical News Today [2008.09.24]

Researchers Find Link Between Organ Transplants, Cancer
Source: MedicineNet Kidney Cancer Specialty [2008.07.17]

Fatal Organ Transplants From Rabies
Source: MedicineNet Rabies Specialty [2004.07.02]

AAKP Supports Bill To Clarify Laws Regarding Incentives For Organ Donation, USA
Source: Transplants / Organ Donations News From Medical News Today [2008.09.24]

more>>

Published Studies Related to Zenapax (Daclizumab)

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. [2007.05]

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. [2007.03]

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. [2007.03]

Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. [2006.07.15]

Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. [2006.05]

more>>

Clinical Trials Related to Zenapax (Daclizumab)

Human Anti-Tac (Daclizumab) to Treat JIA-Associated Uveitis [Completed]

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis [Active, not recruiting]

ANTI-TAC THERAPY FOR UVEITIS [Completed]

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk [Completed]

Zenapax to Treat Multiple Sclerosis [Active, not recruiting]

more>>